Abstract: Programmed death ligand 1 (PD-L1) is a protein which, when interacting with its receptor programmed death 1, acts as a negative regulator of the antitumor T-cell-mediated immune response. The prognostic value of PD-L1 expression in renal cell carcinoma (RCC) has been controversial. In this study, the prognostic value of PD-L1 expression in RCC was evaluated by analyzing PD-L1 immunoreactivity in tumor cells and tumorinfiltrating immune cells (TIICs) in 346 RCC patients with longterm follow-up. PD-L1 positivity in tumor cells was associated with higher World Health Organization nucleolar grade (P < 0.001), recurrence (P = 0.011), and death due to RCC (P = 0.031). PD-L1 positivity in TIICs was associated with higher nucleolar grade (P < 0.001), higher T-stage (P = 0.031), higher N-stage (P = 0.01), recurrence (P = 0.007), and death due to RCC (P = 0.001). A significant positive association of time to cancer-specific death with both PD-L1-positive tumor cells and TIICs were also found. The data indicate that RCC patients with PD-L1-positive tumor cells and TIICs are at significant risk for cancer progression and the expression may be used as a complementary prognostic factor in the management of RCC patients.
R enal cell carcinoma (RCC) is the most common cancer in the kidney and it is estimated to be the 12th most common cancer worldwide. The highest incidence of RCC is found in Europe and the United States with an incidence of ∼64,000 and 72,000 new RCC cases, respectively. 1 Although patients with localized RCC usually have a good clinical course, patients with metastatic disease at time of diagnosis show a significantly worse prognosis. About 33% of patients diagnosed with RCC will present with metastatic disease and almost 30% of patients treated for localized disease will develop metastatic disease during follow-up. 2 Predicting the clinical outcome is still challenging in the management of RCC patients and new prognostic markers are urgently needed. 3 It is well established that T lymphocytes (T cells) have the capability to recognize and destroy various tumor cells. [4] [5] [6] Inhibitory T-cell signaling has been shown to limit the antitumor immune response, also termed immune surveillance. 7 The ability to evade antitumor immunity is considered one of the hallmarks of cancer, and it has been suggested that tumors use immunosuppressive mechanisms for this escape. 8 Programmed death ligand 1 (PD-L1) is a costimulatory ligand which, when interacting with its receptor programmed death 1 (PD-1), acts as a negative regulator of the antitumor T-cell-mediated immune response. 9, 10 PD-L1 expression can be induced in activated T cells and macrophage-lineage cells. Recent reports have also identified aberrant PD-L1 expression in tumor cells in several different malignancies. [11] [12] [13] [14] [15] PD-L1 expression in tumor cells or tumor-infiltrating immune cells (TIICs) may therefore contribute to inhibition of immune surveillance, and facilitating tumor progression. In addition, immune checkpoint blockades targeting PD-1 or PD-L1 have shown promising therapeutic efficacy in several malignancies. [16] [17] [18] The clinicopathologic and prognostic significance of PD-L1 expression have been investigated in a number of human malignancies. [19] [20] [21] [22] [23] [24] PD-L1 expression is associated with poor prognosis in several cancer types among them melanoma and gastric cancer even though association with better clinical outcome in other cancer types have been found. [25] [26] [27] PD-L1 expression has also been suggested as a prognostic marker in RCC, although contradictory results have been reported. [28] [29] [30] [31] [32] A limitation in the majority of previous investigations is however that the association between PD-L1 expression and cancer prognosis have focused on PD-L1 expression only in tumor cells. In addition, comparisons between studies have to be done with caution, since many different anti-PD-L1 antibodies have been used.
In the present study, our aim was to investigate the prognostic value of PD-L1 expression in RCC by analyzing PD-L1 immunoreactivity evaluated by 2 different antibody clones, SP142 and 28.8, both used as companion diagnostics for clinical trials with nivolumab and atezolizumab.
MATERIALS AND METHODS

Case and Tissue Collection
The present study includes 346 patients diagnosed with RCC and treated with radical nephrectomy or nephron sparing surgery at the Örebro University Hospital, Örebro, Sweden, between January 1986 and December 2011. The study cohort was followed for cancer-specific and all-cause mortality until December 2015. Clinical features including sex, body mass index, smoking habits, cause of death, and local and/or distant recurrence were collected from medical records. The cohort is previously described by Grabowska et al. 33 Formalin-fixed paraffin-embedded (FFPE) blocks and corresponding hematoxylin and eosin slides from all cases were retrieved and re-reviewed by 2 experienced pathologists (M.F. and F.G.). The pathologists reevaluated tumor specimens based on the TNM classification according to American Joint Committee on Cancer (AJCC) 2018 8th ed. The histologic subtype of RCC was classified according to the 2016 World Health Organization (WHO) Tumor Classification. Each tumor was moreover graded according to the WHO nucleolar grading system. In addition, the pathologists circled tumor and tumor adjacent normal areas on hematoxylin and eosin slides corresponding to the FFPE blocks.
The study was approved by the regional ethics review board (ethical approval number 2010/135 and 2015/353).
Immunohistochemistry (IHC)
Three tissue cores with a diameter of 0.6 mm were collected from each tumor and tumor adjacent normal area, respectively. Tissue microarrays (TMAs) were constructed with a Galileo TMA CK 4500 array and 4-µm sections were used for IHC.
In the present study, 2 different commercially available anti-PD-L1 antibodies were used, SP142 (Spring Bioscience, Pleasanton, CA) and 28.8 (Abcam, Cambridge, MA). Immunohistochemical analysis for PD-L1 with the 2 different antibodies was performed on serial tissue sections on the automated Benchmark; Ventana ULTRA Staining platform. Optimal conditions for the primary rabbit monoclonal antibody anti-PD-L1 (clone SP142) were to steam heat at 100ºC with ethylenediaminetetraacetic acid for 92 minutes in pH 8. The slides were then incubated with the antibody at 1:30 dilution followed by revelation with the amplification system U OptiView DAB IHC version 5. Optimal conditions for the rabbit monoclonal antibody anti-PD-L1/CD27 (clone 28.8) for antigen retrieval were to steam heat at 100ºC with ethylenediaminetetraacetic acid for 32 minutes in pH 8, followed by 1-hour incubation with the antibody diluted 1:400, followed by revelation system U OptiView DAB IHC version 5 without the amplification step. Tissue from tonsils was used as a positive control for all stainings. All PD-L1-stained slides were scanned and acquired using a Pannoramic 250 instrument (3D Histec, Budapest, Hungary). The system converted the glass slides into digital slides at high resolutions using the software Case viewer version 2.1 (3D Histec).
Evaluation of PD-L1 Expression
The immunostaining was assessed by 2 independent observers (F.G. and V.K.) blinded to all clinical data as follows. Each TMA core was first semiquantitatively deemed to be populated by at least 1000 tumor cells. PD-L1 positivity was defined as ≥ 5% specific membranous and/or cytoplasmatic staining of tumor cells or immune cells. All types of immune cells, including macrophages, dendritic cells, and lymphocytes were counted together.
Statistics
The aim of this study was to evaluate the PD-L1 expression in patients diagnosed with RCC and correlate the levels of immunoreactivity with clinicopathologic features. Comparisons between clinicopathologic features and PD-L1 expression were evaluated by χ 2 or Fisher exact test. For survival analyses, Kaplan-Meier with logrank test and multivariate Cox proportional hazards regression model adjusted for age at surgery, nucleolar grade (1, 2, 3, and 4), AJCC stage (1, 2, 3, and 4), tumor size (< 70 and ≥ 70 mm), and calendar year of operation (1986-1993, 1994-2001, and 2002-2010) were used. Overall agreement between the 2 anti-PD-L1 antibody clones SP142 and 28.8 was estimated using Cohen κ coefficient (κ). Two-sided P-values <0.05 were considered statistically significant. All data were analyzed using SPSS version 22 (IBM, Armonk, NY) and STATA release 14 (Stata Corp., College Station, TX). 
RESULTS
The clinicopathologic features of the patients are summarized in Table 1 . A total number of 346 patients were eligible for analyses. The mean age in the cohort was 64.7 years (range, 28 to 93 y). Of the patients, 195 (56.4%), 77 (22.3%), 66 (19.1%), and 8 (2.2%) presented with pT1, pT2, pT3, and pT4 tumors, respectively. Approximately 50% of the tumors were AJCC stage 1. The histologic subtypes included clear cell RCC (ccRCC) (n = 273), papillary carcinoma type I (n = 21), papillary carcinoma type II (n = 22), chromophobe RCC (n = 23), collecting duct RCC (n = 1), unclassified RCC (n = 3), RCC consistent with mucinous tubular and spindle cell carcinoma (n = 2), and papillary carcinoma with sarcomatoid differentiation (n = 1). The median follow-up period was 6.6 years (range, 0 to 27.1 y). At last follow-up, 171 of the 346 study subjects were deceased, of which 76 patients died from RCC.
PD-L1 Immunoreactivity in Tumor Cells and TIICs and Clinicopathologic Features
In the present study, the PD-L1 expression was evaluated in tumor cells and TIICs in patients with RCC by using 2 different anti-PD-L1 antibody clones, SP142 and 28.8. We also evaluated PD-L1 expression in the tumor adjacent normal tissue within the same patient. PD-L1 immunoreactivity in tumor cells was found in 15 (4.4%) of the analyzed patients when using SP142 and in 50 (14.9%) patients when using 28.8 ( Fig. 1) . PD-L1 expression in TIICs was observed in 26 (7.6%) patients with SP142 and in 61 (18.2%) patients with 28.8 (Fig. 2) . PD-L1 positivity in immune cells in tumor adjacent normal tissue was detected in 8 (2.5%) and 10 (3.1%) patients with SP142 and 28.8, respectively.
PD-L1 immunoreactivity in tumor cells was associated with higher WHO nucleolar grade (P < 0.001), recurrence (P = 0.011), and death due to RCC (P = 0.031) when identified with clone 28.8 (Table 2) . When using SP142 for PD-L1 detection, similar associations were found except for death due to RCC (Table 3) .
PD-L1 positivity in TIICs was associated with higher WHO nucleolar grade (P < 0.001), recurrence (P = 0.007), pT-stage (P = 0.031), N-stage (P = 0.01), and RCC-specific death (P = 0.001) when using 28.8 (Table 2) . When using SP142 for detection of PD-L1, associations were observed between PD-L1 positivity and WHO nucleolar grade (P = 0.004), pT-stage (P = 0.038), and death due to RCC (P = 0.009) ( Table 3) .
No associations between PD-L1 positivity in inflammatory cells located in tumor adjacent normal tissue and clinicopathologic features was found.
PD-L1 Immunoreactivity in Tumor Cells and TIICs and Clinical Outcome in RCC
The median follow-up of the cohort used in the present study was 6.6 years, and 76 patients died from RCC. According to Kaplan-Meier analysis, PD-L1-positive tumor cells detected with either 28.8 or SP142 were significantly associated with shorter cancer-specific survival compared with PD-L1-negative tumor cells (P = 0.006 and 0.012, respectively). Similar associations were observed when comparing PD-L1 expression in TIICs for detection with either of 28.8 or SP142, (P = 0.009 and <0.001, respectively). The 5-year cancer-specific survival rates were 68.6% for patients with PD-L1-positive tumors and 86.7% for patients with PD-L1-negative tumors, detected with antibody 28.8. For patients with PD-L1-positive tumors detected using antibody clone SP142, the 5-year cancer-specific survival rates were 59.3%, and for PD-L1-negative tumors 84.9%. A reduced cancer-specific survival rate was also observed in patients with PD-L1-positive TIICs compared with patients with PD-L1-negative TIICs, when using either antibody clone (Table 4) .
PD-L1 in Tumor Cells and TIICs as a Potential Prognostic Factor in RCC
The prognostic value of PD-L1 immunoreactivity in tumor cells or TIICs was evaluated for RCC-specific death (Table 5 ). Univariate Cox regression analyses revealed a significant positive association of time to cancer-specific death with both PD-L1-positive tumor cells and PD-L1-positive TIICs (for 28.8, P = 0.008 and 0.011, respectively and for SP142, P = 0.015 and 0.001, respectively). The association remained significant after adjusting for other clinical factors, both for positive PD-L1 expression in tumor cells detected by 28.8 (P = 0.049) and for positive PD-L1 expression in TIICs detected by SP142 (P = 0.005). In this study we also measured the agreement of positive PD-L1 immunoreactivity between the anti-PD-L1 clone 28.8 and SP142. A higher number of PD-L1-positive TIICs and tumor cells were detected with antibody 28.8.
A κ value of 0.21 was found for PD-L1 expression in tumor cells and of 0.37 for the expression in TIICs. These values indicate a fair amount of agreement between the antibodies. None to slight agreement was observed for PD-L1 expression in inflammatory cells in tumor adjacent normal tissue based on the κ value of 0.09.
DISCUSSION
Treatments targeting the PD-1/PD-L1 pathway have achieved promising results in patients with melanoma and bladder cancer, and PD-L1 expression as a predictive biomarker has been investigated intensively. However, its value as prognostic marker for RCC is still controversial. [28] [29] [30] 34 In this study, we demonstrate that RCC patients with either PD-L1-positive tumor cells or TIICs are at significant risk of poor clinical outcome, including decreased RCC-specific survival. In addition, our data indicate that PD-L1 expression can be used as a complementary prognostic factor in the management of RCC patients.
PD-L1, also known as B7 homolog 1, has been implicated as a negative regulator of antitumoral T-cell-mediated Positive associations between PD-L1 expression and poor clinical outcomes has been reported for a number of different malignancies including lung cancer, gastric cancer, esophageal cancer, and pancreatic cancer. 21, 37 The knowledge about PD-L1 expression and its prognostic value in RCC is however quite limited, and also partly contradictory. In 2004, the first investigation of PD-L1 expression in RCC was reported by Thompson et al. 38 When applying IHC on 196 ccRCC specimens, the results revealed that patients with high tumor or lymphocyte PD-L1 expression exhibited aggressive tumors, and had an increased risk of death due to RCC. However, since the anti-PD-L1 antibody used was reliable only for immunohistochemical analysis of fresh-frozen tissues, the duration of follow-up was limited (median 2 y).
In the present study, performed on a large cohort of RCC patients with long-term follow-up, we add support for the value of tumor PD-L1 expression as a prognostic marker in RCC. Our data show that PD-L1 expression in tumor cells is associated with worse clinicopathologic features, including higher WHO nucleolar grade and recurrence. Similar results were recently reported by Abbas and colleagues. When investigating PD-L1 expression in a cohort of 177 patients diagnosed with ccRCC, they revealed associations between tumor PD-L1 positivity and higher AJCC stage, pT-stage, and metastasis. 28 They were however unable to demonstrate PD-L1 status as a significant independent prognostic marker. In the current study, we identified PD-L1 expression in tumor cells as an independent marker for RCC-specific mortality. Other recent studies have also reported that patients with tumor PD-L1 expression have a significantly shorter RCC-specific survival compared with patients with PD-L1-negative tumors. 29, 31, 39 Although there has been a substantial amount of studies investigating the association between PD-L1 expression in tumor cells and RCC prognosis there are limited knowledge about the prognostic value of immune cell-based PD-L1 expression. Thompson and colleagues reported in 2004 that patients with enhanced levels of tumor-infiltrating lymphocyte-associated B7 homolog 1 had an increased risk of RCC-specific mortality. Since then, only a few investigations have been published with the aim to investigate the impact of immune cell-based PD-L1 expression in RCC, showing contradictory results. 34, 38, 39 This is to our knowledge the first evaluation of the prognostic value of PD-L1 expression in TIICs in a large cohort of RCC patients with long-term follow-up. In line with the results presented by Thompson and colleagues, we found that PD-L1 expression in TIICs is associated with adverse clinicopathologic features, including higher nucleolar grade and AJCC stage. Our data further revealed that PD-L1 expression in TIICs was associated with a significant increased risk of RCCspecific mortality, independently of other clinical factors. Our data support the hypothesis that immune cells within the renal tumor microenvironment contribute to facilitating tumor progression.
The results in the present study suggest 2 different mechanisms by which the T-cell-mediated antitumor immunity could be suppressed, potentially leading to a tumor promoting micro-milieu: (1) PD-L1 expression in tumor cells; and (2) PD-L1 expression in TIICs. Furthermore, our observation that PD-L1 expression in tumor cells or TIICs is associated with adverse clinical features and shorter RCC-specific survival may be of significance in the clinical management of RCC patients. Here we show that PD-L1 expression has the potential to be used as an independent marker to identify patients with higher risk of dying from their disease.
In the present study we, for the first time, compare the expression of PD-L1 in tumor cells and TIICs with 2 different 8, SP142 , 22C3, and SP263). They reported increased percentage of PD-L1-stained cancer cells when using 28.8 compared with SP142. The reverse scenario was observed for the affinity for PD-L1 on tumor-infiltrating lymphocytes; thus, the varying ability of 28.8 and SP142 to detect PD-L1 in tumor cells and TIICs that we found in this study was expected. 40 Along with the use of different anti-PD-L1 antibody clones, the use of different staining protocols and scoring system for defining PD-L1 positivity makes it hard to perform accurate comparisons between different PD-L1 expression analyses.
In the present study, TMAs were constructed containing FFPE RCC specimens. The TMA technique is time-effective and cost-effective and entails experimental uniformity, but it can also be viewed as a limitation due to the small amount of tissue sampled. 41 Nevertheless, despite evaluating the PD-L1 expression on TMAs, possibly underestimating the true PD-L1 expression, we found that PD-L1 expression in either tumor cells or TIICs might have prognostic value in RCC. Owing to small numbers, we were not able to analyze the prognostic value of PD-L1 in specific subtypes of RCC. This can be of value in future investigations.
In conclusion, PD-L1 expression in tumor cells and TIICs is associated with poor clinical outcome and decreased RCC-specific survival, and can therefore be useful as a complementary prognostic factor in the management of RCC patients.
